It is so important to remember that these patients are riddled with cancer. They have unfortunately failed all conventional therapies due to the advanced nature of their disease. Keeping this in mind, PAA have been able to demonstrate that at the lowest dose, this drug reduces the tumour marker in question by upto 65%. These are big developments for a company with such a tiny market cap. Whether or not this tumour marker actually correlates to tumour size/spread and life expectancy is another matter. Only time will tell.
In addition, it is important to remember that this Phase 1 trial has one primary objective, and that is to determine the drug's safety profile in humans. We have achieved this and more so far. Add to this the fact that oral dosing has been demonstrated to result in adequate blood concentrations of the drug in question and we have ourselves the very very early stages of a potential company making drug.
This company, as i've said many times before, will have a market cap in excess of $5omill soon.
